HLA
ADVM

Hamilton Lane Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Hamilton Lane Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,462
Closed -$592K – 67
2020
Q4 		$592K Buy
+5,462
New +$676K 0.22% 43

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hamilton Lane Advisors's ADVM Position: Q1 2021 in Review

Hamilton Lane Advisors sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 5,462 shares — an estimated $592K sold.

Hamilton Lane Advisors first reported a position in ADVM in Q4 2020 and held it in 1 quarter. The position peaked at $592K in Q4 2020. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • Hamilton Lane Advisors reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 5,462 Adverum Biotechnologies shares in Q1 2021, an estimated $592K.
  • Hamilton Lane Advisors first reported a position in Adverum Biotechnologies in Q4 2020 and held it in 1 quarter.
  • Hamilton Lane Advisors's Adverum Biotechnologies position peaked at $592K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on Hamilton Lane Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.